Advertisement Spectrum Pharma names new SVP, acting CFO - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Spectrum Pharma names new SVP, acting CFO

Spectrum Pharmaceuticals, a biotechnology company with integrated commercial and drug development operations with a primary focus in oncology, has named Brett Scott as the new senior vice president (SVP) and acting chief financial officer (CFO) of the company.

Scott will be responsible for all financial aspects of the company and will report directly to the chairman, CEO and president of the company, Rajesh Shrotriya.

Most recently Scott was the CFO at Biolase Technology, a California-based medical device company that designs, manufactures and markets advanced dental, cosmetic and surgical lasers, and related products worldwide.

Spectrum Pharma chairman president CEO Rajesh Shrotriya said that Brett’s financial and management skills, including experience with capital raising, mergers and acquisitions, and public healthcare companies will prove to be very valuable for them.

"Brett will lead the effort to build the financial and accounting infrastructure to support our growth of product revenue from our two FDA approved anticancer drugs, Zevalin and Fusilev," Shrotriya said.